kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant, human HGFR / c-MET, protein kinase domain, 10 µg  

Recombinant, human HGFR / c-MET, protein kinase domain, 10 µg

Recombinant human hepatocyte growth factor receptor / c-MET, amino acids K956-S1390, protein kinase domain, active enzyme

Alternate names: recombinant, human, protein kinase, MET HGFR, HGF/SF receptor, Proto-oncogene c-Met, Tyrosine-protein kinase Met

More details


Availability: on stock

345,00 €

Background: MET (Mesenchymal epithelial transition factor), also known as hepatocyte growth factor receptor (HGFR) is a proto-oncogenic receptor tyrosine kinase. The endogenous ligand for MET is hepatocyte growth factor/scatter factor (HGF), a disulfide-linked heterodimeric molecule produced predominantly by mesenchymal cells. Abberant activation of the HGF/MET pathway leads to a variety of cancers. MET mutation is associated with a poor prognosis as it can trigger tumor growth, angiogenesis and metastasis.

Recombinant human MET kinase (amino acids K956-S1390, GenBank entry NM_000245.2), contains an N-terminal GST-His6 fusion tag with a thrombin cleavage site

Theoretical MW: 78.8 kDa (fusion protein)
Expression system: Baculovirus infected Sf9 cells
Storage buffer: 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 5 mM DTT, 4 mM reduced glutathione, 20% glycerol
Protein concentration: 0.144 mg/ml (Bradford method using BSA as standard protein)
Method for determination of Km value & specific activity: Filter binding assay MAFC membrane
Specific activity : 105,000 pmol/mg min

Entrez Gene ID: 4233
UniProtKB:   P08581

Ordering information: shipped on dry ice

Use our c-Met - SPR Binding Assay for comprehensive kinetic characterization of your small molecule kinase inhibitors. 


Figure: Real-time kinetic analysis of kinase inhibitor Erlotinib binding to c-MET using surface plasmon resonance.

Please contact our application specialists to obtain more information and an individual quote tailored to your specific needs.

Product specific literature:

Organ SL, Tsao MS.(2011) “An overview of the c-MET signaling pathway.” Ther Adv Med Oncol.;3(1 Suppl):S7-S19.

Giannoni P, Scaglione S, Quarto R, Narcisi R, Parodi M, Balleari E, Barbieri F, Pattarozzi A, Florio T, Ferrini S, Corte G, de Totero D.(2011) “An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease.” Haematologica. 96(7):1015-23.

Liu X, Newton RC, Scherle PA. (2011) “Development of c-MET pathway inhibitors.” Expert Opin Investig Drugs. 2011 Sep;20(9):1225-41.